Remove 2019 Remove Diabetes Remove Labelling
article thumbnail

Novo Nordisk gets NICE okay for obesity drug Wegovy

pharmaphorum

Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approved label. The 2019 Health Survey for England estimated 28% of adults in England were obese and a further 36% were overweight, according to NICE.

Labelling 105
article thumbnail

SGLT-2 Inhibitors

RX Note

Introduction The treatment approach for type 2 diabetes mellitus has undergo a shift from the traditional glucose-centric approach to the new cardiorenal-metabolic approach. This change emphasizes a comprehensive approach for reducing the risk of diabetes-related complications.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Moving towards oral delivery of biologics

European Pharmaceutical Review

Of the 175 new drugs approved by the US Food and Drug Administration (FDA) between 2016 and 2019, most were biologics. Results from the first open-label, single-centre study of RT-101,6 which was conducted in Australia, were reported at the start of 2020. Diabetes Therapy. 2019 [cited 2023Feb]. 2019;10(2):437–49.

article thumbnail

Tackling multimorbidity through collaboration

pharmaphorum

Importantly, multimorbidity occurs as clusters of diseases, and whilst there are different views on what the clusters are and how many exist, Lord says that most would agree there are three main clusters: Cardiovascular/metabolic – including heart disease, hypertension and Type 2 diabetes. 2019; 40:554–563. The hallmarks of aging.

article thumbnail

A history of Johnson & Johnson

pharmaphorum

Robert Wood’s granddaughter, Mary Lea, was the first baby to be used on the baby powder label. billion) hit the company in 2019. During this tenure, J&J entered into the areas of vision care, mechanical wound closure and diabetes management. Litigation & controversy. Acquisitions post-Janssen.

Vaccines 126
article thumbnail

Glaucoma

RX Note

Other risk factors include advancing age, family history, ethnicity, corticosteroid use, myopia, type 2 diabetes mellitus , cardiovascular disease and hypertension. It is generally linked to raised intraocular pressure, which is the main treatable risk factor , but can also occur when the intraocular pressure is within the normal range.

Dosage 52
article thumbnail

Chronic Disease Solutions: Spotlight on COVID-19 and its Impact on Heart Disease

PharmD Live

However, patients who have better control of many chronic illnesses, including diabetes, hypertension, hyperlipidemia, COPD, and heart failure, have lower risks of future disease and adverse clinical outcomes unrelated to COVID-19, such as MI, strokes, cardiac arrhythmias, etc. Fam Med Community Health. 2021 Apr;9(2):e000741.Retrieved